Peter L. Havens, MS, MD
Medical director, HIV, Children's Hospital of Wisconsin; professor, Pediatrics and Epidemiology, Medical College of Wisconsin.
HIV infection, Pharmacokinetics, drug side effects/metabolic complications, adolescents.
Medical degree, University of Missouri School of Medicine, Kansas City, 1980; residency: The Children's Hospital, Boston, 1981-1984; fellowship, Pediatric Infectious Diseases, The Children's Hospital, Boston, 1984-1987, and Anesthesia (Intensive Care), The Children's Hospital, Boston, 1985-1987.
- 1987, American Board of Pediatrics, Certification in General Pediatrics
- 1987, Americal Board of Pediatrics, sub-specialty certification in Pediatric Critical Care
- 1995, American Board of Pediatrics, sub-specialty certification in Pediatric Infectious Diseases
- 1995, American Board of Pediatrics, re-certification in Pediatric Critical Care
- 2001, American Board of Pediatrics, re-certification in Pediatric Critical Care
- 2001, American Board of Pediatrics, re-certification in Pediatric Infectious Diseases
- 2008, American Board of Pediatrics, re-certification in Pediatric Infectious Diseases
Massachusetts and Wisconsin (WI - #28368)
Upjohn Award, University of Missouri, Kansas City School of Medicine, 1981; Most Outstanding Teacher Award, Pediatric House Staff, Medical College and Children's Hospital, Milwaukee, 1988, 1989, 2005, 2009; Honor Roll of Outstanding Teachers, Pediatric House Staff, Medical College of Wisconsin and Children's Hospital of Wisconsin, Milwaukee, 1991; Wisconsin Maternal and Child Health Coalition Achievement Award: "Outstanding Sustained Public Information Program", along with all members of the Pediatric HIV Coordinating Committee of Milwaukee, 1993; Edward J. Lennon Endowed Clinical Teaching Award, Medical College, 1993; A.H. Robins/Wyeth-Ayerst Laboratories Miracle Maker Award for Excellence in Patient Care, service to the community, and health education, 1994; E. Grey Dimond, MD, Take Wing Award for "...exceptional professional or personal accomplishments that contribute to the field of medicine..." University of Missouri-Kansas City School of Medicine, Kansas City, 1995; Award for Innovation, Association for Care of Children's Health (ACCH), honorable mention, with other members of the Wisconsin HIV Primary Care Support Network, 1997; Medical College of Wisconsin Society of Teaching Scholars, 1997; Milwaukee Magazine: One of the Best Physicians in Milwaukee, 2000, 2004, 2008, 2012; Included in "Best Doctors in America" 2002-2010; Wisconsin Chapter, American Academy of Pediatrics, 2002 Pediatrician of the Year, 2002; AIDS Resource Center of Wisconsin "Twenty Giving Twenty" award, for service to children and families with HIV in Wisconsin, 2005; "Clinician's Clinician," for clinical excellence, voted by the faculty of the Department of Pediatrics, Medical College, 2005; AIDS Resource Center of Wisconsin award for leadership, for role in programs for prevention of mother to child transmission of HIV in Wisconsin, 2007; Presidential Volunteer Award, US Agency for International Development (USAID) for work in the Pediatric ART Centers of Excellence, Lusaka and Livingstone, Zambia, 2007.
- **Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani, RM, Liu NX, Muenz LR, Harris DR, Havens PL, and the Adolescent Trials Network for HIV/AIDS Interventions. Pharmacokinetics of Antiretroviral Regimens Containing Tenofovir Disoproxil Fumarate and Atazanavir/Ritonavir in Adolescents and Young Adults with HIV Infection - study ATN056. Antimicrob Agents Chemother. 2008; 52:631-37.
- **Robbins BL, Capparelli EV, Chadwick EG, Yogev R, Serchuck L, Worrell C, Smith ME, Alvero C, Fenton T, Heckman B, Pelton SI, Aldrovandi G, Borkowsky W, Rodman J, and Havens PL, for the PACTG 1038 Team. Pharmacokinetics of High-Dose Lopinavin/Ritonavir with and without Saquinavir or Non-Nucleoside Reverse Transcriptase Inhibitors in HIV Infected Pediatric and Adolescent Patients Previously Treated with Protease Inhibitors - Study PACTG P1038. Antimicrobial Agents Chemother. 2008; 52:3276-3283.
- Beheti G, Kiser JJ, Havens PL, Fletcher CV. Plasma and Intracellular Pharmacokinetic Analysis of Tenofovir in HIV-1 Infected Patients. Antimicrob Agents Chemother. 2011; 55(11):5294-9.
- **Havens PL, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR, Van Loan MD, Lui N, Lujan-Zilbermann J, Baker A, Kapogiannis BG, Mulligan K, the Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions 063 study team. Vitamin D3 Decreases Parathyroid Hormone in HIV-Infected Youth Being treated with Tenofovir: A Randomized, Placebo-Controlled Trial. Clin Infect Dis. 2012; 54(7):1013-1025.
- **Havens PL, Mulligan K, Hazra R, Flynn P, Rutledge B, Van Loan MD, Lujan-Zilbermann J, Kapogiannis BG, Wilson CM, Stephensen CB, for the Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions 063 study team. Serum 25-Hydroxyvitamin D Response to Vitamin D3 Supplementation 50,000 IU Monthly in Youth with HIV-1 Infection. Journal of Clinical Endocrinology & Metabolism. 2012; epub August 2012.
- Ryan White CARE Act Part D grant to support the WI HIV Primary Care Support Network: $847,713 yearly for 5 years. Medical director - 5% funded effort.
- Ryan White CARE Act Part B grant to support the WI HIV Primary Care Support Network: $200,000. Medical director - 1.9% funded effort.
- Therapeutic Leadership Group of the Adolescent Medicine Leadership Group of the Adolescent Medicine Trials Network for HIV/AIDS intervention (ATN). NIH grant number U01 HD40533-05. 10% funded effort.
- Protocol Chair, Adolescent Trials Network study 109 "A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Effectiveness of Vitamin D3 50,000 IU every 4 Weeks to Increase Bone Mineral Density and Decrease Tenofovir-Induced Hyperparathyroidism in Youth with HIV Infection Being Treated with Tenofovir-Containing Combination Antiretroviral Therapy: A Multi-Center Study of the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN)". $3,282,191. 10% funded effort.
- Protocol Chair, Adolescent Trials Network Study 117 "Renal, Endocrine, and Bone Changes in Response to Treatment with Coformulated Emtricitabine-Tenofovir for Pre-Exposure HIV Prophylaxis (PrEP) in HIV Uninfected Young Men Who Have Sex with Men. Sub-Study of ATN 110 and/or ATN 113: A Multi-Interventions (ATN)". $1,032,941. 10% funded effort.
- Protocol chair, Adolescent Trials Network study "Effect of Vitamin D Treatment on Soluble Mediators of Inflammation: ATN 063 Further Laboratory Studies and Analysis", a sub-analysis of ATN 063. $180,670. 5% funded effort. Pending approval.
Children's Research Institute
Children's Corporate Center, Suite 450
999 North 92nd Street
Wauwatosa, WI 53226
Phone: (414) 337-7070
Fax: (414) 337-7093
Investigator in the areas of: